Literature DB >> 15063733

Mutation of the major 5' splice site renders a CMV-driven HIV-1 proviral clone Tat-dependent: connections between transcription and splicing.

Jens Bohne1, Hans-Georg Kräusslich.   

Abstract

Efficient transcription from the human immunodeficiency virus type 1 long terminal repeat (HIV-1 LTR) promoter is dependent on the viral transactivator Tat. To generate a Tat-independent proviral plasmid, we replaced the promoter in the HIV-1 LTR with the immediate early promoter of cytomegalovirus. Transfection of this plasmid yielded Tat-independent production of infectious HIV-1. Tat-independent expression was lost, however, when the major 5' splice site in the HIV-1 genome was mutated and no HIV-1-specific RNA or protein was detected. This defect was restored when a Tat expression plasmid was cotransfected. Our results support recent reports indicating an influence of the recognition of splice sites on efficient transcriptional elongation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063733     DOI: 10.1016/S0014-5793(04)00277-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution.

Authors:  Florian K M Schur; Wim J H Hagen; Michaela Rumlová; Tomáš Ruml; Barbara Müller; Hans-Georg Kräusslich; John A G Briggs
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

2.  Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.

Authors:  Barbara Müller; Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  Analysis of human immunodeficiency virus type 1 Gag ubiquitination.

Authors:  Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Role of the SP2 domain and its proteolytic cleavage in HIV-1 structural maturation and infectivity.

Authors:  Alex de Marco; Anke-Mareil Heuser; Bärbel Glass; Hans-Georg Kräusslich; Barbara Müller; John A G Briggs
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

5.  Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques.

Authors:  Géraldine Arrode-Brusés; Ramakrishna Hegde; Yuhuai Jin; Zhengian Liu; Opendra Narayan; Yahia Chebloune
Journal:  Vaccine       Date:  2012-03-02       Impact factor: 3.641

6.  Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry.

Authors:  Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.

Authors:  Barbara Müller; Maria Anders; Hisashi Akiyama; Sonja Welsch; Bärbel Glass; Krisztina Nikovics; Francois Clavel; Hanna-Mari Tervo; Oliver T Keppler; Hans-Georg Kräusslich
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

8.  Foamy virus nuclear RNA export is distinct from that of other retroviruses.

Authors:  Jochen Bodem; Tanja Schied; Richard Gabriel; Matthias Rammling; Axel Rethwilm
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

9.  Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

Authors:  Dirk Jochmans; Maria Anders; Inge Keuleers; Liesbeth Smeulders; Hans-Georg Kräusslich; Günter Kraus; Barbara Müller
Journal:  Retrovirology       Date:  2010-10-15       Impact factor: 4.602

10.  Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor.

Authors:  Marina R Alexander; Adam K Wheatley; Rob J Center; Damian F J Purcell
Journal:  Nucleic Acids Res       Date:  2010-01-13       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.